Outpatient Treatment for Klebsiella pneumonia and MRSA

First-line Treatment Options

The Infectious Diseases Society of America recommends trimethoprim-sulfamethoxazole (TMP-SMX) plus amoxicillin as a first-line regimen for outpatient treatment of co-infection with Klebsiella pneumonia and MRSA 1, 2
The American Thoracic Society suggests that fluoroquinolones (levofloxacin or moxifloxacin) provide excellent coverage against both typical and atypical respiratory pathogens including Klebsiella 2

The Infectious Diseases Society of America recommends TMP-SMX plus amoxicillin as a first-choice combination regimen for outpatient treatment of co-infection with Klebsiella pneumonia and MRSA, providing coverage for both MRSA and Klebsiella pneumoniae 1, 2
Linezolid alone (600 mg orally twice daily) is an alternative option, providing coverage for MRSA and having some activity against gram-negative pathogens, but consider adding a fluoroquinolone if Klebsiella is the predominant pathogen or in severe cases 1, 2

The Infectious Diseases Society of America recommends 7-14 days of therapy for pneumonia, individualized based on clinical response 1, 2
For uncomplicated skin infections with MRSA, 5-10 days of therapy is typically sufficient 1

The American Thoracic Society suggests hospitalization for patients with severe pneumonia, respiratory distress, or sepsis, and for those with significant comorbidities, advanced age, or immunosuppression 2, 3
Clinical reassessment within 48-72 hours is essential to ensure appropriate response to therapy, and if no improvement occurs within 72 hours, consider culture and sensitivity testing if not already done, and possible hospitalization for intravenous therapy 1, 3